ClinicalTrials.gg
Sign In
WithdrawnNCT05786170Updated Mar 27, 2023

ERILs Und SNILs Unter SOC

An interventional study of diffusion-weighted magnetic resonance imaging in Stroke, Acute, sponsored by Medical University of Vienna. Withdrawn. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2023-03-27.

Sponsored by Medical University of Vienna · Not applicable, Interventional, and Diagnostic

Why this study was withdrawn
lack of research funding
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years to 100 Years
Sex
All
01

Study summary

  1. How many ERILs occur in caucasian patients with LAA stroke during 7 days on standard treatment?
  2. How many SNILs occur between 7 and 30 days after acute ischemic event on standard treatment?
  3. How many of during acute event diagnosed lesions (ERILs) are (still) detectable after 30 days?
  4. Are there relevant risk faktors for the occurence of ERILs and SNILs (eg Diabetes or Biomarkers)?
Read the detailed description

In this trial, patients will be observed if they develop early recurrent ischemic lesions (= ERILs) or silent neurologic ischemic lesions (= SNILs) after acute stroke or transitoric ischemic attack (TIA) based on atherothrombosis (LAA-stroke) on standard therapy during 30 days (day 7 and day 30 after acute event) via DW-MRI (diffusion-weighted magnetic resonance imaging).

We want to investigate if diffusion-weighted imaging of silent brain infarcts occuring during standard therapy is a suitable surrogate outcome measure for interventional studies

02

Conditions studied

  • Stroke, Acute

Browse trials for

03

In context

Stroke

7,441 studies on the registry are indexed under Stroke; 2,012 are open to participants now.

Browse Stroke studies →

Lead sponsor

Medical University of Vienna is the lead sponsor of 1,105 studies on the registry; 182 are open to participants now.

Browse Medical University of Vienna studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • LAA stroke or TIA
  • ERILs or SNILs detected in initialDW-MRI
  • signed informed consent

Exclusion criteria

Exclusion Criteria:

  • planned surgical intervention
  • iv Thrombolysis
  • atrial fibrillation
  • contra indications against DW-MRI
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    magnetic resonance imaging

    DW-MRI after ischemic stroke

    Diagnostic Test: diffusion-weighted magnetic resonance imaging

Interventions

  • Diagnostic testdiffusion-weighted magnetic resonance imaging

    diffusion-weighted magnetic resonance imaging

06

What researchers measure

Primary outcomes

  1. 1. How many ERILs occur in caucasian patients with LAA stroke during 7 days on standard treatment?

    DW-MRI to detect lesions

    Time frame: 7 days after acute stroke

Secondary outcomes

  1. 2. How many SNILs occur between 7 and 30 days after acute ischemic event on standard treatment and how many of during acute event diagnosed lesions (ERILs) are (still) detectable after 30 days?

    DW-MRI to detect lesions

    Time frame: 30 days after acute stroke

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2019.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2023
First posted
Mar 27, 2023
StartEst.
Sep 2019
Primary completionActual
Jul 5, 2021
CompletionActual
Jul 5, 2021
Last update
Mar 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05786170
Lead sponsor
Medical University of Vienna
Collaborators
Medical University Innsbruck
Responsible party
Christa Firbas MD (MD, Medical University of Vienna) — Principal investigator
First posted
Mar 27, 2023
Start date
Sep 2019 (estimated)
Primary completion
Jul 5, 2021
Completion
Jul 5, 2021
Last update
Mar 27, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Stroke →

Other studies from this sponsor

Medical University of Vienna →

Start the discussion